Showing results (411-420 of 537) with videos related to

Sort By:
Pageof 54
Neuromodulation : Journal of the International Neuromodulation Society|August 14, 2012
Long-term outcome in occipital nerve stimulation patients with medically intractable primary headache disordersAnn Chang Brewer, Terrence L Trentman, Michael G Ivancic, et al.
Headache|August 28, 2020
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% ResponseGregor Broessner, Uwe Reuter, Jo H Bonner, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialHong Sun, David W Dodick, Stephen Silberstein, et al.
Headache|April 13, 2019
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical TrialsStephen D Silberstein, Peter McAllister, Xiaoping Ning, et al.
Mayo Clinic Proceedings|July 22, 2023
Prevalence of and Risk Factors for Post-traumatic Headache in Civilian Patients After Mild Traumatic Brain Injury: A TRACK-TBI StudyHåkan Ashina, David W Dodick, Jason Barber, et al.
Cephalalgia : an International Journal of Headache|August 19, 2021
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studiesRichard B Lipton, David W Dodick, David Kudrow, et al.
Headache|February 1, 2008
Predictors of migraine headache recurrence: a pooled analysis from the eletriptan databaseDavid W Dodick, Richard B Lipton, Peter J Goadsby, et al.
Headache|February 12, 2014
Education and decision making at the time of triptan prescribing: patient expectations vs actual practicePaul G Mathew, Jelena M Pavlovic, Alyssa Lettich, et al.
Headache|March 4, 2025
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort studyDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|March 29, 2020
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension studyStewart J Tepper, Messoud Ashina, Uwe Reuter, et al.
Pageof 54